Pricing Log in Create free account
Saturday 17 October 2026 Export IMTX’s income statement to Excel — free account

Immatics N.V.

IMTX Healthcare Biotechnology

Immatics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $54.6 million, down 67.6% from fiscal 2024. In the quarter to June 2026, revenue grew 97.7%, EPS grew 19.7% and free cash flow fell 44.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.72 0.42 −5.88%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
3/9
Altman Z
6.75
Beneish M
−1.36
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 7.50
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — 1 — —
Sell — — — — — — — — — — — —
Insider Ownership 6.56%

Capital & Financial Ratios $m

Market Cap 1,070.00
Revenue 49.20
Net Income (237.04)
Free Cash Flow (240.08)
Net Debt (270.28)
Current Ratio 7.54 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (4.78) (negative: loss-making)
P/S ratio 18.67 (above 10: high)
P/B ratio 1.98
Past 5Y EPS Growth —
This Y EPS Growth (12.12%) (below 0%: weak)
Next Y EPS Growth (2.54%) (below 0%: weak)
Next Y revenue growth (16.26%) (below 0%: weak)
Next 5Y EPS Growth (0.06%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 13.2×, against a ten-year median of 9.3×; over the ten years it ranged from 1.2× in 2022 to 27.2× in 2026.
P/S against its own 10 years 72.68%
10-year low 10-year high
P/B against its own 10 years 11.65%
10-year low 10-year high
EV/Sales against its own 10 years 70.51%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2018 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 236 256 391 270
Receivables 4 6 7 7
Inventory — — — —
Other 245 419 172 222
486 681 570 499
2023 2024 2025 Q'26
Payables 27 22 21 39
ST’ Debt — — — —
Other 31 9 6 13
169 74 49 66

Compound Annual Growth %

10y 5y 3y
Sales — 11.81% (33.06%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 39.34% 34.60%

Revenue $m

Mar Jun Sep Dec Year
’26 9 11 — — —
’25 20 5 6 24 55
’24 33 20 56 60 169
’23 11 24 6 17 58
’22 115 18 15 33 182
’21 9 6 8 18 41
’20 8 8 9 14 31
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (49) (70) — — —
’25 (36) (47) (55) (62) (200)
’24 (35) (35) (39) (62) (171)
’23 (25) (8) (33) 86 20
’22 122 52 (42) (27) 105
’21 (20) (24) (21) (32) (97)
’20 0 (13) (57) (16) (86)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (50) (71) — — —
’25 (39) (49) (56) (63) (208)
’24 (45) (38) (42) (63) (189)
’23 (30) (19) (40) 76 (14)
’22 121 51 (43) (30) 99
’21 (21) (26) (23) (34) (103)
’20 0 (18) (59) (16) (93)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.50) (0.53) — — —
’25 (0.35) (0.66) (0.49) (0.34) (1.82)
’24 (0.03) (0.18) (0.09) 0.48 0.15
’23 (0.28) (0.35) (0.35) (0.32) (1.30)
’22 1.52 (0.23) (0.32) (0.23) 0.58
’21 (0.41) (0.46) (0.51) (0.30) (1.75)
’20 (0.18) (20.19) (3.30) 18.88 (5.45)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 0.01 9.71 8.67 10.12 5.75 5.90 6.68 3.30

Analyst estimates 2026–2028

Powerpack
High — — 9.80 11.16 17.48 18.42 13.60 13.14 13.77 12.41
People
People Employees — — 2 2 198 255 293 343 423 407
Revenue/emp, $m — — 1.89 9.22 0.16 0.16 0.62 0.17 0.40 0.13
Income, $m
Income, $m Revenue — — 4 18 31 41 182 58 169 55
Gross margin, % — — 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT — — (32) (32) (230) (110) 44 (105) 23 (225)
EBT margin, % — — (858.22) (176.09) (734.70) (268.49) 24.32 (179.63) 13.70 (411.13)
Net income — 0 (32) (32) (230) (110) 40 (105) 16 (222)
Depreciation — — 2 4 4 6 7 8 13 14
Per share, $
Per share, $ Revenue — — 0.11 0.56 0.65 0.65 2.71 0.73 1.59 0.45
Earnings — — (0.98) (0.98) (5.45) (1.75) 0.59 (1.30) 0.15 (1.82)
Cash flow — — 0.63 2.14 (1.78) (1.54) 1.57 0.24 (1.62) (1.63)
Capex — — (0.01) (0.06) (0.16) (0.11) (0.10) (0.41) (0.17) (0.06)
Free cash flow — — 0.61 2.08 (1.94) (1.64) 1.47 (0.17) (1.79) (1.70)
Book value — — 0.15 (1.23) 2.17 0.45 3.34 3.02 5.88 4.48
Shares, m — — 33 33 48 63 67 81 106 122
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 11.43 0.00 39.50 0.00
P/S — — 0.00 0.00 13.28 20.56 3.16 14.78 4.46 23.53
P/B — — 6.13 0.00 4.97 29.70 2.57 3.54 1.21 2.35
EV/Sales — — 0.00 0.00 7.96 16.73 2.30 10.73 2.94 16.36
EV/FCF — — 0.00 3.39 (3.26) (6.65) 4.24 (46.06) (2.62) (4.30)
Cash, $m
Cash, $m Operating cash flow — — 21 71 (86) (97) 105 20 (171) (200)
Capex — — 0 (2) (8) (7) (6) (33) (18) (8)
Free cash flow — — 20 69 (93) (103) 99 (14) (189) (208)
Balance, $m
Balance, $m Working capital — — 1 55 178 68 285 317 608 522
Total debt — — — 4 28 43 34 — — —
Net debt — — (1) (103) (208) (157) (156) (236) (256) (391)
Shareholders’ equity — — 5 (41) 104 28 225 244 622 548
Returns, %
Returns, % ROA — — (43.13) (22.54) (117.79) (47.88) 12.42 (21.39) 2.52 (31.99)
ROIC — — (565.68) 0.00 0.00 0.00 28.96 (961.55) (7.14) (82.33)
ROE — — 106.81 176.20 (722.34) (166.40) 31.24 (44.84) 3.80 (38.00)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Immatics N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BCAX Bicara Therapeutics Inc. $1.2B — (loss-making) — — n/m −72.95% (below 0%: shrinking) — 0.00% Compare
DMRA Galecto, Inc. $1.2B — (loss-making) — — n/m −877.51% (below 0%: shrinking) 0.00% 0.00% Compare
VOR Vor Biopharma Inc. $1.1B — (loss-making) — — n/m −47.59% (below 0%: shrinking) 0.00% — Compare
NBTX Nanobiotix S.A. - Sponsored ADR $1.1B — (loss-making) — −71.69% (below 0%: shrinking) n/m −177.26% (below 0%: shrinking) 0.00% 0.00% Compare
REPL Replimune Group, Inc. $1.1B — (loss-making) — — n/m +5.04% (above 0%: growing) 0.00% 0.00% Compare
IMTX Immatics N.V. $1.1B — (loss-making) — (loss-making) +97.71% (above 0%: growing) n/m −44.41% (below 0%: shrinking) 100.00% (734.95%)
JANX Janux Therapeutics, Inc. $1.1B — (loss-making) — (loss-making) +2,238.72% (above 0%: growing) n/m +150.57% (above 0%: growing) 100.00% (308.66%) Compare
MNKD MannKind Corporation $1.0B — (loss-making) — (loss-making) +42.92% (above 0%: growing) n/m −399.41% (below 0%: shrinking) 72.99% (0.32%) Compare
SVRA Savara Inc. $973.9M — (loss-making) — (loss-making) — n/m −14.05% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $1.1B — — +42.92% — −60.27% 0.00% 0.00%

All 614 Biotechnology stocks →

Immatics N.V. (IMTX) key facts

  • Concern: Immatics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $54.6 million, down 67.6% from fiscal 2024.
  • Immatics N.V. (IMTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, IMTX traded at $6.72, a market capitalization of $1.1 billion.
  • Return on equity was −38.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 6.75 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Immatics N.V. (IMTX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/IMTX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com